15 January 2025
15 January 2025
Article doesn't exist
Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.
The WHO has reported a “high” regional and national risk from the haemorrhagic virus while the global risk remains low.
CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.
The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.
In 2023, medical dermatology represented 52% of Almirall's income with a turnover of EUR465.2m ($477.36m).
The acquisition builds on a 2017 option agreement and subsequent 2018 licensing deal with Glycotope.
The application is based on outcomes from the Phase III LAVENDER trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
